Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO

Executive Summary

Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.

You may also be interested in...



Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg

The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.

Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg

The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.

Medeva Fluvirin Production Returns To Market-Demand Level

Production of Medeva's influenza vaccine Fluvirin has returned to levels of market demand following improvements in the manufacturing process, the company said.

Related Content

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel